This review depicts multiple aspects of management for cancer-free carriers of germline P/LPVs in BRCA1 and BRCA2 genes, including risk-reducing options, secondary prevention (screening), as well as treatment of iatrogenic sequela of risk-reducing interventions. The gene discussed is BRCA2; the disease is cancer.